Your browser doesn't support javascript.
HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019.
Bruni, Laia; Saura-Lázaro, Anna; Montoliu, Alexandra; Brotons, Maria; Alemany, Laia; Diallo, Mamadou Saliou; Afsar, Oya Zeren; LaMontagne, D Scott; Mosina, Liudmila; Contreras, Marcela; Velandia-González, Martha; Pastore, Roberta; Gacic-Dobo, Marta; Bloem, Paul.
  • Bruni L; Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - IDIBELL, l'Hospitalet de Llobregat, Spain; Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP CB06/02/0073), Madrid, Spain. Electronic address: lbruni@iconcologia.net.
  • Saura-Lázaro A; Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - IDIBELL, l'Hospitalet de Llobregat, Spain. Electronic address: asaura.lazaro@iconcologia.net.
  • Montoliu A; Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - IDIBELL, l'Hospitalet de Llobregat, Spain. Electronic address: amontoliu@iconcologia.net.
  • Brotons M; Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - IDIBELL, l'Hospitalet de Llobregat, Spain; Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP CB06/02/0073), Madrid, Spain. Electronic address: mbrotons@iconcologia.net.
  • Alemany L; Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - IDIBELL, l'Hospitalet de Llobregat, Spain; Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP CB06/02/0073), Madrid, Spain. Electronic address: lalemany@iconcologia.net.
  • Diallo MS; Data and Analytics Unit, Department of Analysis, Planning & Monitoring, UNICEF, New York, USA. Electronic address: mamsdiallo@unicef.org.
  • Afsar OZ; Maternal, Neonatal & Adolescent Health Unit, Health Section, UNICEF, New York, USA. Electronic address: oafsar@unicef.org.
  • LaMontagne DS; Center for Vaccine Innovation and Access, PATH, Seattle, USA. Electronic address: slamontagne@path.org.
  • Mosina L; Division of Country Health Programmes, Vaccine-preventable Diseases and Immunization (VPI), World Health Organization Regional Office for the Europe, Copenhagen, Denmark. Electronic address: mosinal@who.int.
  • Contreras M; Comprehensive Family Immunization Unit, Pan American Health Organization, PAHO/WHO, Washington, DC, USA. Electronic address: contrermar@paho.org.
  • Velandia-González M; Comprehensive Family Immunization Unit, Pan American Health Organization, PAHO/WHO, Washington, DC, USA. Electronic address: velandiam@paho.org.
  • Pastore R; Division of Country Health Programmes, Vaccine-preventable Diseases and Immunization (VPI), World Health Organization Regional Office for the Europe, Copenhagen, Denmark. Electronic address: pastorero@who.int.
  • Gacic-Dobo M; Immunization Analysis & Insights Vaccines and Biologicals, World Health Organization, Geneva, Switzerland,. Electronic address: gacicdobom@who.int.
  • Bloem P; Life Course and Integration/ EPI, Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland. Electronic address: bloemp@who.int.
Prev Med ; 144: 106399, 2021 03.
Article in English | MEDLINE | ID: covidwho-1139631
ABSTRACT
WHO/UNICEF estimates for HPV vaccination coverage from 2010 to 2019 are analyzed against the backdrop of the 90% coverage target for HPV vaccination by 2030 set in the recently approved global strategy for cervical cancer elimination as a public health problem. As of June 2020, 107 (55%) of the 194 WHO Member States have introduced HPV vaccination. The Americas and Europe are by far the WHO regions with the most introductions, 85% and 77% of their countries having already introduced respectively. A record number of introductions was observed in 2019, most of which in low- and middle- income countries (LMIC) where access has been limited. Programs had an average performance coverage of around 67% for the first dose and 53% for the final dose of HPV. LMICs performed on average better than high- income countries for the first dose, but worse for the last dose due to higher dropout. Only 5 (6%) countries achieved coverages with the final dose of more than 90%, 22 countries (21%) achieved coverages of 75% or higher while 35 (40%) had a final dose coverage of 50% or less. When expressed as world population coverage (i.e., weighted by population size), global coverage of the final HPV dose for 2019 is estimated at 15%. There is a long way to go to meet the 2030 elimination target of 90%. In the post-COVID era attention should be paid to maintain the pace of introductions, specially ensuring the most populous countries introduce, and further improving program performance globally.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Uterine Cervical Neoplasms / Papillomavirus Infections / Papillomavirus Vaccines / COVID-19 Topics: Long Covid / Vaccines Limits: Female / Humans Country/Region as subject: Europa Language: English Journal: Prev Med Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Uterine Cervical Neoplasms / Papillomavirus Infections / Papillomavirus Vaccines / COVID-19 Topics: Long Covid / Vaccines Limits: Female / Humans Country/Region as subject: Europa Language: English Journal: Prev Med Year: 2021 Document Type: Article